EUVIMEDOdkrijte EUVIMED
CrossrefInformačná karta

Case Report: Splenorenal shunt management after liver transplantation in a recipient with situs inversus totalis

Mei Li, Chenyang Dong, Siming Qu, Zhitao Li, Zhuo Cheng, Chenxuan Li, Xiafei Xia, Junlin Liu, Deling Wei, Zongrui Jin, Hanfei Huang

Frontiers in Medicine · 2026-11-04 · 13

DOI: 10.3389/fmed.2026.1986837 ↗
AbstraktBibliografické údaje

Abstrakt

Situs inversus totalis (SIT) alters graft positioning and vascular reconstruction during liver transplantation. A 56-year-old man with SIT, decompensated hepatitis B cirrhosis and hepatocellular carcinoma received a 558-g deceased-donor whole-liver graft, with a graft-to-recipient weight ratio of 0.60%. The graft was implanted in the native left-sided hepatic fossa in a reversed orientation. Postoperative CT showed a large splenorenal shunt and heterogeneous graft enhancement. Portal vein velocity fell from 44.7 cm/s on postoperative day (POD) 1 to 25 cm/s on POD3–4 and was 32 cm/s on POD5. Endovascular occlusion was abandoned on POD5 because venography showed aneurysmal dilatation and the procedural risk was judged excessive. Open ligation of the approximately 3-cm shunt was performed on POD6, preserving the main renal vein. Portal vein velocity was 30 cm/s after ligation, 37 cm/s on POD7 and 42 cm/s on POD9. Total bilirubin decreased from 158.6 μmol/L on POD4 to 70.5 μmol/L on POD13; the international normalized ratio was 1.49 on POD6 and 1.02 on POD14. The patient was discharged on POD27. Imaging showed no tumor recurrence at approximately 19 months, and alpha-fetoprotein was 7.32 ng/mL at approximately 23 months. This case describes surgical treatment of suspected portal steal in an SIT recipient when endovascular shunt occlusion was unsuitable.

Vedomosti, ktoré zodpovedajú vašej práci.

Od bezplatného začiatku cez osobnú rešerš literatúry až po kompletný Research Suite.

Zobraziť tarify →

Sú zahrnuté všetky plné texty vydavateľov?

Nie. Bibliografické záznamy, abstrakty a plné texty sú odlišné typy obsahu. To, či je plný text dostupný, závisí od zdroja, Open Access a vašich existujúcich licencií. Tarif EUVIMED nenahrádza dodatočné práva vydavateľa.

Zobraziť tarify →